Secteurs & marchés
NTU develops gut-based compound to support weight loss and metabolic health
PHOTO: EurekAlert
Market Info | Health & Lifestyle | Pharmaceuticals and Biotech
Date: 1 March 2026
Region: ASEAN-O
Country: Singapore
Sector: Health & Lifestyle
Sub-sector: Pharmaceuticals and Biotech
Section: Market Trends
Theme: Innovation in weight management and metabolic health solutions
Researchers from the Nanyang Technological University have developed a new orally administered, natural compound designed to support weight management by targeting the gut microbiome and reducing dietary fat absorption. This innovation differs from traditional anti-obesity treatments, which typically focus on appetite suppression, glucose regulation, or metabolic stimulation. The project is being developed in collaboration with longevity biotech firm Aria Bioscience Pte Ltd, with the long-term goal of translating this discovery into commercial nutraceutical products and potential therapeutic applications.
The compound works locally in the intestine by blocking a receptor involved in lipid absorption, thereby reducing the amount of fat transported to the liver. At the same time, it promotes the growth of beneficial gut bacteria that produce short-chain fatty acids, which are associated with reduced inflammation, improved gut barrier function, and better metabolic health outcomes. Preclinical animal studies demonstrated reduced weight gain and lower liver fat accumulation without observable toxic side effects.
This development occurs amid a global obesity crisis, with more than one billion people affected worldwide and rising rates of chronic diseases such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. In Singapore, dietary fat consumption has increased from about 94g per day in 2019 to 100g per day in 2022, according to the National Nutrition Survey, reflecting changing urban dietary habits and lifestyle risks.
From a commercial perspective, Aria Bioscience plans to advance human clinical trials to develop the technology into medical-grade nutraceutical supplements before exploring therapeutic drug applications. This strategy aligns with Singapore’s broader ambition to strengthen its biotech innovation ecosystem by accelerating the translation of academic research into market-ready healthcare solutions.
In the long term, this technology could drive growth in the natural weight management and preventive healthcare markets across Southeast Asia, further strengthening Singapore’s position as a global biomedical innovation hub.
